

1 Patterns of contraceptive use through
2 later reproductive years: a prospective
3 cohort study of Australian women with
4 chronic disease

5
6 Melissa L. Harris^{1,2*}, Nicholas Egan^{1,2}, Peta M. Forder^{1,2}, Deborah Bateson^{3,4}, Deborah
7 Loxton^{1,2}

8
9 ¹ Centre for Women's Health Research, College of Health, Medicine and Wellbeing, The
10 University of Newcastle, Newcastle, New South Wales, Australia.

11 ² Hunter Medical Research Institute, Newcastle, New South Wales, Australia.

12 ³ Family Planning NSW, Ashfield, New South Wales, Australia

13 ⁴ Discipline of Obstetrics, Gynaecology and Neonatology, Faculty of Medicine and Health,
14 University of Sydney, Sydney, Australia

15
16 * Corresponding Author

17 Email: Melissa.Harris@newcastle.edu.au (Melissa L. Harris)

18
19 Running Title: Contraception and chronic disease through later reproductive years

20

ABSTRACT

21 **Background:** Pregnancies among women with chronic disease are associated with poor
22 maternal and fetal outcomes. There is a need to understand how women use or don't use
23 contraception across their reproductive years to better inform the development of
24 preconception care strategies to reduce high risk unintended pregnancies, including among
25 women of older reproductive age. However, there is a lack of high-quality longitudinal
26 evidence to inform such strategies. We examined patterns of contraceptive use among a
27 population-based cohort of reproductive aged women and investigated how chronic disease
28 influenced contraceptive use over time.

29 **Methods and Findings:** Contraceptive patterns from 8,030 women of reproductive age from
30 the Australian Longitudinal Study on Women's Health (1973-78 cohort), who were at potential
31 risk of an unintended pregnancy were identified using latent transition analysis. Multinomial
32 mixed-effect logistic regression models were used to evaluate the relationship between
33 contraceptive combinations and chronic disease. Contraception non-use increased between
34 2006 and 2018 but was similar between women with and without chronic disease (13.6% vs.
35 12.7% among women aged 40-45 years in 2018). When specific contraceptive use patterns
36 were examined over time, differences were found for women with autoinflammatory diseases
37 only. These women had increased odds of using condom and natural methods (OR=1.20, 95%
38 CI=1.00, 1.44), and sterilisation and other methods (OR=1.61, 95% CI=1.08, 2.39) or no
39 contraception (OR=1.32, 95% CI=1.04, 1.66), compared to women without chronic disease
40 using short-acting methods and condoms.

41 **Conclusion:** Potential gaps in the provision of appropriate contraceptive access and care exist
42 for women with chronic disease, particularly for women diagnosed with autoinflammatory
43 conditions. Development of national guidelines as well as a clear coordinated contraceptive

44 strategy that begins in adolescence and is regularly reviewed during care management through
45 their main reproductive years and into perimenopause is required to increase support for, and
46 agency among, women with chronic disease.

47 **Keywords:** chronic disease; contraceptive methods; long-acting reversible contraception;
48 pill; withdrawal; women; cohort study; longitudinal

49

50

51

52 INTRODUCTION

53 Unintended pregnancy is highest among young women, but there is also a growing consensus
54 that it is a significant public health issue for women of older reproductive age [1, 2]. In addition,
55 the prevalence of chronic disease among women of childbearing age is on the rise. In Australia
56 it is estimated that around 30% of women will be diagnosed with at least one chronic health
57 condition during their reproductive years [3]. This trend is predicted to increase over the
58 coming decade, with chronic disease prevalence increasing substantially across successive
59 generations. For women with chronic disease, unintended pregnancies are associated with
60 serious adverse maternal and perinatal outcomes such as congenital abnormalities, early
61 pregnancy loss, and stillbirth [4-7]. Use of effective contraception is recommended as a key
62 strategy to allow these women to plan pregnancies for times of optimal health, or to provide
63 sufficient time to discontinue potentially teratogenic medications and switch to medications
64 which have greater compatibility with pregnancy. However, contraceptive counselling among
65 chronic disease populations remains low [8, 9]. Given chronic disease is on the rise and these
66 women report unintended pregnancy rates at similar or higher rates than the general population,
67 understanding how they use or don't use contraception is critical to tailoring contraceptive
68 counselling interventions for women with chronic disease as they move through their
69 childbearing years [8, 10, 11].

70 Despite this, there is limited population-level evidence regarding the contraceptive practices of
71 women with chronic disease, and no studies have examined contraceptive patterns using
72 nationally representative longitudinal data. Of the few available studies, the findings have been
73 equivocal, driven by a reliance on retrospective cross-sectional study designs, differences in
74 contraceptive methods examined and a focus on small single disease samples [10, 12, 13]. As
75 such, the prevalence of contraceptive use and types of methods employed have varied widely
76 across chronic disease populations with contraceptive use found to range from around 30% to

77 as high as 99% [14-16]. Only one study has longitudinally examined contraceptive use among
78 women with chronic disease of childbearing age using state-based insurance claims data [17].
79 While they found only one-third of women with chronic disease were prescription
80 contraceptive users (compared to 40% of women without a chronic condition), they were
81 unable to examine a range of contraceptive options and they failed to account for women not
82 at risk of pregnancy. Further, while previous studies have involved women with chronic disease
83 across the reproductive life span, recent Australian research suggests that contraceptive
84 patterns differ markedly by life stage and over time [18, 19]. It is therefore important to take a
85 lifecourse approach to contraceptive use among women with chronic disease to understand
86 contraceptive practices as women transition through their childbearing years. This study aimed
87 to establish an evidence-base regarding the contraceptive practices of women with chronic
88 disease by examining patterns of contraceptive use over time among an Australian cohort of
89 women born 1973-78 who have been prospectively followed for over 20 years.

90 **MATERIALS AND METHODS**


91 **Overview of study design**

92 Data were obtained from the 1973-78 cohort of the Australian Longitudinal Study on Women's
93 Health (ALSWH), a national population-based study examining health and wellbeing among
94 Australian women. Women were randomly sampled through the national health insurer's
95 database (Medicare). This cohort has been found to be largely representative of the population
96 of women in this age group [20]. These women have completed surveys in 1996, 2000 and then
97 on a three-yearly schedule thereafter.

98 **Participants**

99 This analysis focused on women who completed Surveys 4, 6 or 8 conducted in 2006 (aged
100 28-33 years), 2012 (aged 34-39 years) and 2018 (aged 40-45 years). These time points provided

101 measurements across women's main reproductive years. Of the 14,247 women who completed
102 the baseline survey in 1996, 9,604 women were eligible for linked data analysis and completed
103 the questions related to contraceptive use at the selected analysis time points (Figure 1). At
104 each survey, women were considered not at risk of an unintended pregnancy if they reported
105 any of the following: no male partner, hysterectomy, currently pregnant, trying to become
106 pregnant, infertile partner, or partner with low or zero sperm count. Excluding women who
107 were not at risk at all time points (N=1,574), the final sample for analysis included 8,030
108 women. Women included in this analysis had a similar demographic profile to the full 1973-
109 78 cohort at baseline in 1996 (Supplementary Table S1).



110

111 **Figure 1. Determination of eligible sample.**

112 *Percentage of women at each survey who completed contraceptive questions but were excluded due to being not at risk of an unintended
113 pregnancy: 2006 = 36%, 2012 = 31%, 2018 = 28%.

114 **Measures**

115 *Contraceptive use*

116 Contraceptive use was measured at each survey. Contraceptive patterns were derived from the
117 question “What forms of contraception do you use now?” At each survey, contraception was
118 measured with 14 response options (participants were able to select more than one option).
119 Women were also asked if they had had a tubal sterilisation or if their partner had had a
120 vasectomy. For this analysis, responses were collapsed into eight groups based on
121 contraceptive efficacy: sterilisation (tubal sterilisation or vasectomy); long-acting reversible
122 contraception (LARC; the progestogen intrauterine system, the copper intrauterine device and
123 the progestogen-only implant); short-acting hormonal contraception (progestogen-only
124 contraceptive pill, combined oral contraceptive pill, oral contraception of unknown type,
125 vaginal ring and depot injection); condoms; natural methods (withdrawal and fertility-based
126 awareness methods); emergency oral contraception; other contraception; and no contraception
127 [19].

128 *Chronic diseases*

129 Chronic disease was measured at each survey by the presence or absence of seven physical
130 chronic diseases that have been associated with poor maternal and fetal outcomes. These
131 included diabetes, cardiac disease (including hypertension), asthma, autoinflammatory
132 arthropathies and connective tissue disease (e.g., rheumatoid arthritis [RA] and systemic lupus
133 erythematosus [SLE]), inflammatory bowel disease (IBD), multiple sclerosis, and thyroid
134 disease. Chronic diseases were ascertained using multiple data sources (self-report survey,
135 state-based hospital admissions data, pharmaceutical prescriptions and disease-specific

136 medical claims from general practitioner and specialist care) and employing disease-specific
137 algorithms (developed in concert with clinical experts) to increase chronic disease accuracy in
138 this population. Detailed information on the methods employed are described elsewhere [21].

139 *Covariates*

140 Time-varying covariates were measured at each survey. Sociodemographic variables included
141 age, highest educational qualification (no formal qualifications, school/higher school
142 certificate; trade/certificate/diploma; university/higher degree), area of residence (categorised
143 according to the Accessibility/Remoteness Index of Australia (ARIA+) classification system
144 as: major cities; inner regional; outer regional/remote/very remote), relationship status
145 (partnered; unpartnered), and country of birth (Australia; other English speaking; other).

146 Health care card holder status (a concession card provided for government-subsidised health
147 care) was also included as a surrogate for socioeconomic status (yes; no). Health-related factors
148 included smoking status (current smoker; ex-smoker; non-smoker) and body mass index
149 (underweight [<18.5 kg/m²]; healthy [≥ 18.5 and <25 kg/m²]; overweight [≥ 25 and <30 kg/m²];
150 obese [≥ 30 kg/m²]) [22].

151 Reproductive health factors included history of pregnancy (yes; no) and history of pregnancy
152 termination (yes; no). Given that contraception is often used for non-contraceptive reasons, the
153 presence or absence of self-reported gynaecological conditions such as polycystic ovarian
154 syndrome and endometriosis (yes; no) as well as the frequent experience of menstrual
155 symptoms such as irregular periods, heavy period or severe period pain were also included
156 (yes; no).

157 **Ethics**

158 All data for this project were obtained from the ALSWH (see www.alswh.org.au/ for further
159 details), approved under Expression of Interest process (EOI A696) and provided in de-

160 identified form. This project has ongoing ethical clearance from the University of Newcastle
161 and University of Queensland’s Human Research Ethics Committees. Ethical approval for
162 linkage of ALSWH survey data to the Admitted Patients Data Collections (APDC) was
163 received from the NSW Population and Health Services Research Ethics Committee and other
164 equivalent state and territory-based committees. Linkage to the National Death Index (NDI)
165 was approved by the Australian Institute of Health and Welfare Ethics Committee. Women
166 provided explicit written consent to participate in the ALSWH as well as for linkage to de-
167 identified administrative health records prior to 2005. From 2005, an ‘opt-out’ consent process
168 was approved by the data custodians and relevant ethics committees for data linkage, with
169 participants regularly reminded of this process. ALSWH participants who decline health record
170 linkage are excluded from data linkage requests.

171 **Statistical analysis**

172 Contraceptive data were entered into separate latent transition models evaluating three to eight
173 latent statuses. Establishing the optimal LTA model was conducted in a similar fashion to
174 Harris et al. [19] and was based on clinical interpretability, latent class separation and
175 goodness-of-fit statistics. Women were assigned a latent status at each survey they completed
176 where they were at risk of an unintended pregnancy, up to a maximum of three time points.
177 These latent statuses could be the same or vary over time. The probabilities of women
178 transitioning being latent statuses over time are presented in Supplementary Table S2. Each
179 latent status described one or more contraceptives being used concurrently. For example, Status
180 1 (“short-acting and condom”) refers to women who used short-acting contraceptive methods
181 and condoms simultaneously. A classify-analyse approach was then used to assign each
182 participant to a latent status at each time point, according to the latent status with the greatest
183 posterior probability. Latent transition analysis was performed using PROC LTA procedure
184 (The Methodology Centre, Penn State) in SAS 9.4 software (SAS Institute Inc). The number

185 of time points with latent statuses with low probabilities (<2%) were minimised as this would
186 contribute to numerical estimation issues in the subsequent regression models. Multinomial
187 mixed-effect logistic regression models were developed, with the assigned latent status as the
188 multinomial outcome, participant ID as a random effect to account for correlation between
189 observations on the same participant over time, while controlling for time-varying covariates
190 as fixed effects. We performed a complete case analysis with participants with missing data
191 omitted from the analysis. Models were developed for the presence of any chronic condition
192 and separately for each chronic disease.

193 **RESULTS**

194 **Sample characteristics**

195 In 2006, 25.8% of women (aged 28-33 years) reported at least one chronic disease. This
196 increased to 35.5% by 2018 when aged 40-45 years (Table 1). The most common chronic
197 condition was asthma (17.9% in 2006). Other conditions, including diabetes, cardiac disease,
198 autoinflammatory arthropathies and connective tissue disease, IBD, multiple sclerosis, and
199 thyroid disease each had prevalence rates of less than 5% in 2006. However, the prevalence of
200 each of these conditions had approximately doubled by 2018 when the women were aged 40-
201 45 years. Given the low frequencies of autoinflammatory conditions (AICs; i.e.,
202 autoinflammatory arthropathies and connective tissue disease, IBD, multiple sclerosis, and
203 thyroid disease) these were combined into a single autoinflammatory disease category for
204 subsequent modelling.

205 **Table 1. Proportion of women with chronic disease over the observation period.**

Chronic disease	2006	2012	2018
	Aged 28-33 N=5,402	Aged 34-39 N=5,092	Aged 40-45 N=4,660
	n (%)	n (%)	n (%)
Any physical chronic disease	1,394 (25.8)	1,636 (32.1)	1,656 (35.5)
Diabetes	144 (2.7)	210 (4.1)	246 (5.3)
Cardiac disease	260 (4.8)	396 (7.8)	430 (9.2)
Asthma	965 (17.9)	928 (18.2)	883 (18.9)
^a Autoinflammatory disease	276 (5.1)	469 (9.2)	510 (10.9)
Arthropathies	97 (1.8)	150 (2.9)	186 (4.0)
Inflammatory bowel disease	28 (0.5)	40 (0.8)	53 (1.1)
Thyroid disease	45 (0.8)	155 (3.0)	194 (4.2)
Multiple sclerosis	85 (1.6)	120 (2.4)	116 (2.5)

^aIncludes autoinflammatory arthropathies, inflammatory bowel disease, thyroid disease and multiple sclerosis.

206

207 Comparing women with and without chronic disease in this sample, there were few differences
 208 across sociodemographic, health behaviour and reproductive health characteristics at Survey 4
 209 in 2006 (Table 2). Women with chronic disease were less likely to have a university degree
 210 (42.5% vs. 48.0%), and more likely to report their ability to manage on available income as
 211 impossible or difficult always (16.8% vs. 11.7%). Similar differences were also observed in
 212 2018 when the women were aged 40-45 years.

213 **Table 2: Characteristics of women from the 1973-78 cohort at Survey 4 in 2006 (aged**
 214 **28-33 years), according to chronic disease status (n=5,402).**

Characteristic	Category	Chronic disease status	
		Absent n=4,008 n (%)	Present n=1,394 n (%)
Sociodemographics			
Country of birth	Australia	3,548 (88.5)	1,264 (90.7)
	Other English-speaking background	181 (4.5)	69 (4.9)
	Non-English-speaking background	261 (6.5)	58 (4.2)
	<i>Missing</i>	<i>18 (0.4)</i>	<i>3 (0.2)</i>
Area of residence	Major cities	2,301 (57.4)	763 (54.7)
	Inner regional	985 (24.6)	401 (28.8)
	Outer regional/remote/very remote	722 (18.0)	230 (16.5)
	<i>Missing</i>	<i>0 (0.0)</i>	<i>0 (0.0)</i>

Education	No formal qualifications	30 (0.7)	23 (1.6)
	School certificate/higher school certificate	986 (24.6)	361 (25.9)
	Trade/apprentice/certificate/diploma	1,056 (26.3)	412 (29.6)
	University/higher degree	1,925 (48.0)	593 (42.5)
	<i>Missing</i>	<i>11 (0.3)</i>	<i>5 (0.4)</i>
Relationship status	Partnered	3,228 (80.5)	1,092 (78.3)
	Unpartnered	768 (19.2)	296 (21.2)
	<i>Missing</i>	<i>12 (0.3)</i>	<i>6 (0.4)</i>
Health care card	No	3,520 (87.8)	1,137 (81.6)
	Yes	486 (12.1)	256 (18.4)
	<i>Missing</i>	<i>2 (0.1)</i>	<i>1 (0.1)</i>
Health factors			
Smoking	Non-smoker	2,336 (58.3)	760 (54.5)
	Ex-smoker	870 (21.7)	303 (21.7)
	Current smoker	783 (19.5)	326 (23.4)
	<i>Missing</i>	<i>19 (0.5)</i>	<i>5 (0.4)</i>
	Body mass index	Underweight	137 (3.4)
Healthy		2,329 (58.1)	646 (46.3)
Overweight		910 (22.7)	359 (25.8)
Obese		535 (13.3)	318 (22.8)
<i>Missing</i>		<i>97 (2.4)</i>	<i>40 (2.9)</i>
Reproductive health			
History of pregnancy	No	3,458 (86.3)	1,186 (85.1)
	Yes	526 (13.1)	204 (14.6)
	<i>Missing</i>	<i>24 (0.6)</i>	<i>4 (0.3)</i>
History of termination	No	3,320 (82.8)	1,118 (80.2)
	Yes	687 (17.1)	275 (19.7)
	<i>Missing</i>	<i>1 (0.0)</i>	<i>1 (0.1)</i>
Parity	Zero	1,833 (45.7)	621 (44.5)
	One	797 (19.9)	292 (20.9)
	Two	975 (24.3)	345 (24.7)
	Three or more	403 (10.1)	136 (9.8)
	<i>Missing</i>	<i>0 (0.0)</i>	<i>0 (0.0)</i>
Menstrual symptoms	No	3,397 (84.8)	1,105 (79.3)
	Yes	580 (14.5)	283 (20.3)
	<i>Missing</i>	<i>31 (0.8)</i>	<i>6 (0.4)</i>
History of PCOS*	No	3,942 (98.4)	1,352 (97.0)
	Yes	66 (1.6)	42 (3.0)
	<i>Missing</i>	<i>0 (0.0)</i>	<i>0 (0.0)</i>
History of endometriosis	No	3,893 (97.1)	1,342 (96.3)
	Yes	115 (2.9)	52 (3.7)
	<i>Missing</i>	<i>0 (0.0)</i>	<i>0 (0.0)</i>

216 **Trends in contraceptive use**

217 In 2006, 91.5% of women with chronic disease were using some form of contraception
218 compared to 93.2% of women without chronic disease (Table 3). At this time point, 43.8% of
219 women with chronic disease were using short-acting hormonal contraception compared to
220 46.2% of women without chronic disease. By 2018, these proportions had reduced, but were
221 similar (15.1% vs 15.6%). In 2006, 6.5% and 5.3% of women with and without chronic disease
222 were using LARC, respectively. By 2018, LARC use had increased substantially with 23.7%
223 of women with chronic disease using this method compared to 20.7% of women without
224 chronic disease. A similar increase was noted for sterilisation methods, with relatively low use
225 in 2006 (11.3% vs 9.0%, respectively) and substantially higher use at age 40-45 years in 2018
226 (31.6% vs 33.0%, respectively).

227 **Table 3. Contraceptive trend over time by chronic disease status.**

Contraception	Chronic disease status 2006 (Survey 4) Aged 28-33 years		Chronic disease status 2012 (Survey 6) Aged 34-39 years		Chronic disease status 2018 (Survey 8) Aged 40-45 years		
	No n=4,008 n (%)	Yes n=1,394 n (%)	No n=3,456 n (%)	Yes n=1,636 n (%)	No n=3,004 n (%)	Yes n=1,656 n (%)	
	Any contraception	3,737 (93.2)	1,276 (91.5)	3116 (90.2%)	1463 (89.4%)	2,622 (87.3)	1,431 (86.4)
Condom	1,297 (32.4)	423 (30.3)	899 (26.0%)	419 (25.6%)	534 (17.8)	261 (15.8)	
Short acting ^A	1,853 (46.2)	611 (43.8)	1001 (29.0%)	443 (27.1%)	455 (15.1)	259 (15.6)	
LARC ^B	213 (5.3)	91 (6.5%)	486 (14.1%)	248 (15.2%)	622 (20.7)	393 (23.7)	
Natural methods ^C	503 (12.5)	172 (12.3)	473 (13.7%)	186 (11.4%)	337 (11.2)	177 (10.7)	
Sterilisation ^D	361 (9.0)	157 (11.3)	749 (21.7%)	391 (23.9%)	991 (33.0)	523 (31.6)	
Other methods	347 (8.7)	145 (10.4)	104 (3.0%)	57 (3.5%)	116 (3.9)	73 (4.4)	
Emergency	43 (1.1)	22 (1.6)	21 (0.6%)	14 (0.9%)	6 (0.2)	9 (0.5)	
No contraception	271 (6.8)	118 (8.5)	340 (9.8%)	173 (10.6%)	382 (12.7)	225 (13.6)	
Number of contraceptives	0	271 (6.8)	118 (8.5)	340 (9.8%)	173 (10.6%)	382 (12.7)	225 (13.6)
	1	2,962 (73.9)	976 (70.0)	2558 (74.0%)	1207 (73.8%)	2,204 (73.4)	1,191 (71.9%)
	2	713 (17.8)	280 (20.1)	522 (15.1%)	236 (14.4%)	404 (13.4)	228 (13.8%)
	3+	62 (1.5)	20 (1.4)	36 (1.1%)	20 (1.2%)	14 (0.5)	12 (0.7%)

228 ^A The short-acting category was composed of the pill (91.5%), the minipill (5.8%), injection (2.5%) and vaginal ring (0.7%).
 229 ^B The long-acting reversible contraception (LARC) category was composed of progestogen-only IUD (64.5%), implant (32.2%) and copper IUD (4.0%).
 230 ^C The natural methods category was composed of withdrawal method (88.9%) and fertility awareness methods (20.1%).
 231 ^D The sterilisation category was composed of vasectomy (79.1%) and tubal ligation (21.6%).
 232 Note: Types of contraception do not add to 100% as respondents were able to select multiple methods.
 233 LARC = long-acting reversible contraception.

234 Among women with chronic disease, use of one contraceptive method only was similar over
235 time (70.0% and 71.9% in 2006 and 2018 respectively). Among women with chronic disease,
236 use of two or more contraceptive methods declined from 21.5% in 2006 to 14.5% in 2018.
237 Contraceptive non-use increased over the observation period with 13.6% of women with
238 chronic disease and 12.7% without chronic disease not using any contraception in 2018 (when
239 aged 40-45 years). Emergency contraception was reported with very low frequencies across
240 time for women with and without chronic disease (1.6% vs 1.1% in 2006 and 0.5% vs 0.2% in
241 2018, respectively). Given these low frequencies and the purpose of emergency contraception
242 being to prevent pregnancy where contraception has not been used, misused, or has failed, it
243 was excluded from further analysis.

244 **Contraceptive combinations**

245 A five-status LTA model was selected as the optimal model, given its reasonable clinical
246 interpretability and goodness-of-fit (Supplementary Table S3). Status 1 (Table 4), “short-acting
247 and condom” was characterised by high use of short-acting methods (100% probability) with
248 some supplementation with condoms (15% probability). Status 2, “condom and natural”
249 captured high use of condoms (69% probability) with some supplementation of non-hormonal
250 natural methods (38% probability) and other methods (8% probability). Status 3, “sterilisation
251 and other” was dominated by vasectomy or tubal sterilisation (100% probability) but included
252 supplementation of other methods for some women (16% probability). Status 4, “LARC”
253 included the use of long-acting methods (100% probability), with a small amount of
254 supplementation such as condoms (3% probability). The “no contraception” status (Status 5)
255 captured the absence of contraceptive use (100% probability). Status 1, “short-acting and
256 condom”, was selected as the reference status as it was comprised of two of the most popular
257 contraceptive methods among reproductive-aged women, the pill and condom. This was
258 reflected in the data, with 44% of women in 2006 belonging to Status 1 in 2006 (Supplementary

259 Table S4). As such, Status 1 was appropriate as a baseline contraceptive against which to make
 260 comparisons in the subsequent modelling.

261 **Table 4. Probability of individual contraception contributing to contraceptive patterns**
 262 **over time for Australian women born 1973-78, using a five-status LTA model.**

Latent Status	Latent status description	Item-response probabilities for each status						
		Condom	Short-acting	LARC	Natural	Other	Sterilisation	No contraception
Status 1	Short-acting and condom	0.15	1.00	-	0.03	-	-	-
Status 2	Condom and natural	0.69	0.04	-	0.38	0.08	-	-
Status 3	Sterilisation and other	0.02	0.04	0.06	-	0.16	1.00	-
Status 4	LARC	0.03	-	1.00	-	-	0.01	-
Status 5	No contraception	-	-	-	-	-	-	1.00

263 Note: Dashed cells have probability <0.01. Shaded status (#1, short-acting and condom) was selected as the reference class for subsequent
 264 analysis.

265 Natural methods = withdrawal and fertility-awareness methods.

266 LARC = Long-acting reversible contraception.

267 Contraceptive use patterns over time

268 Women were most likely to remain in the same latent status between time points
 269 (Supplementary Table S2), with women in Status 3 (“sterilisation and other”) in 2006 the most
 270 likely to continue using the same contraception in 2012 (P=0.86). Women in Status 5 in 2006
 271 (“no contraception”) were most likely remain in Status 5 when measured again in 2012
 272 (P=0.32) but had a moderate probability of transitioning to Status 2 (“condom and natural”,
 273 P=0.26) or Status 3 (“sterilisation and other”, P=0.18). Women in Status 1 (“short-acting and
 274 condom) in 2012 had similar probabilities of transitioning to “condom and natural” (P=0.14),
 275 “sterilisation and other” (P=0.17), “LARC” (P=0.15)” and “no contraception” (P=0.13).

276 Contraceptive use by women with chronic disease

277 There was no evidence to support a difference in the patterns of contraceptive use for women
 278 with any chronic disease compared to women without chronic disease (Table 5). When each of
 279 the chronic conditions were examined separately, a difference in contraceptive patterns was
 280 observed only for women with autoinflammatory disease. Women with autoinflammatory

281 disease had increased odds of using condom and natural methods (OR=1.20, 95% CI=1.00,
282 1.44), and sterilisation and other methods (OR=1.61, 95% CI=1.08, 2.39) or no contraception
283 (OR=1.32, 95% CI=1.04, 1.66), compared to women without chronic disease using short-
284 acting methods and condoms (full model results are presented in Supplementary Tables S5-
285 S9).

286 **Table 5. Multinomial mixed-effect models for the effect of chronic disease status on contraceptive use for Australian women, aged 28 to**
 287 **45 across three time points (2006, 2012 & 2018).**
 288

Model	Chronic disease status	Condom & natural	Sterilisation & other	^a LARC	No contraception
		OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
1	Any physical chronic disease	0.97 (0.88, 1.08)	1.23 (0.96, 1.57)	1.12 (0.96, 1.32)	1.07 (0.93, 1.23)
2	Cardiac disease	0.86 (0.67, 1.10)	0.79 (0.52, 1.20)	1.03 (0.78, 1.34)	0.86 (0.67, 1.10)
3	Diabetes	1.28 (0.95, 1.74)	0.84 (0.48, 1.47)	1.34 (0.95, 1.91)	1.28 (0.95, 1.74)
4	Asthma	1.00 (0.85, 1.18)	1.14 (0.84, 1.54)	1.04 (0.86, 1.26)	1.00 (0.85, 1.18)
5	Autoinflammatory disease	1.32 (1.04, 1.66)	1.61 (1.08, 2.39)	1.18 (0.91, 1.53)	1.32 (1.04, 1.66)

289 Reference status = short-acting and condom; reference level for disease = disease not present.
 290 Each model controlled for age, country of birth, area of residence, highest educational qualification, relationship status, health care card holder status, smoking status, body mass index, history of pregnancy, history of
 291 termination, history of miscarriages, menstrual symptoms, history of polycystic ovary syndrome, history of endometriosis, and survey wave.
 292 LARC = Long-acting reversible contraception.
 293 Full model results can be found in Supplementary Tables 5-9.

DISCUSSION

Main findings

By examining contraceptive combinations for women with chronic disease who were at risk of an unintended pregnancy and following these women over a 12-year observation period, we were able to provide an accurate account of contraceptive use (and non-use) for women with diabetes, cardiac disease, AICs and asthma. Although women with chronic disease used contraception at similar rates to women without chronic disease in the community, around 30% were either non-users of contraception or users of low efficacy contraception by age 40-45. However, when individual chronic diseases were examined, there was evidence to suggest that women with AICs were more likely to engage in low efficacy contraception or no contraception compared to other women. Such practices place these women at increased risk of high-risk unintended pregnancy. As such, these findings have the potential to influence the development of targeted clinical interventions and guidelines to help support provision of effective contraception for women with AICs.

Strengths and limitations

Use of nationally representative longitudinal data is a key strength of this study. We were able to examine a comprehensive set of contraceptive methods (including prescription and non-prescription methods) and applied complex statistical modelling to accurately identify contraception use (including contraceptive combinations). We also considered the dynamic nature of contraceptive use and unintended pregnancy risk across the reproductive lifecourse in our analysis [19, 23]. Given 5,046 women were not at risk of an unintended pregnancy for at least one of the time points, this should be standard practice for future longitudinal contraceptive research. A further strength is our approach to chronic disease measurement [21]. No studies have previously employed such comprehensive methods to ascertain chronic disease

among women of reproductive age or applied these to contraceptive research in the context of chronic disease.

However, as we examined contraceptive use at three time points, six years apart, we were not able to identify switching of contraceptive methods in between these periods. Also, we employed a classify-analyse approach to examine changing chronic disease status as well as other key influencing factors, which potentially introduced a degree of measurement error from the latent status classification. There may have been some bias in the sample due to differential loss to follow up, however it is unclear whether women with chronic disease would be more or less likely to have completed surveys. Similar to other longitudinal cohort studies, there is an over-representation of tertiary education women in the ALSWH; however, this is the largest sample examining contraceptive patterns over time for women with chronic disease.

Interpretation

Overall, contraceptive use among women with chronic disease in our study was found to be relatively high, with rates reported above 85% across the observation period. This finding is supported by one population-based study but contrasts with previous cross-sectional Australian and short-term longitudinal international research (although the Australian study found similar rates between those with and without chronic disease).[8, 17, 24] Encouragingly, there were substantial increases in the uptake of LARC and permanent methods by the time women were 40-45 years. Use of highly effective methods among women with chronic disease is supported by a previous population-based international study, although that finding was largely driven by sterilisation [24]. While the use of permanent methods in our study increased over time, with around a third of women using these methods by age 40-45, almost one-quarter were using LARC by this time. This is important as these methods are safe for most women with chronic disease, have low failure rates and provide additional benefits during perimenopause [25]. LARC use among women with chronic disease in this cohort however was found to be

substantially lower than that reported by women with chronic disease in the 1989-95 cohort at similar ages and suggests that there may be a generational shift in the perceptions surrounding the use of LARC, including the suitability of these methods for women of reproductive age with chronic disease [26].

When focused on patterns of contraceptive use across chronic disease groups, only women with AICs were found to differ in their contraceptive practices to women without chronic disease who used short-acting methods and condoms. Interestingly, method choice was complex amongst this group, with these women more likely to engage in permanent contraception or alternatively, low efficacy methods and no contraception. In this cohort, sterilisation was driven by partner vasectomy [19]. For women of older reproductive age with AICs who have completed their families or do not wish to have children, this finding is promising given that partner vasectomy is a more straight forward procedure with fewer risks than female sterilisation [27, 28].

Concerning, however, is the increased use of low efficacy methods and non-contraceptive use among women with AICs. Previous international research has found 70-80% of women of reproductive age with AICs were non-users of prescription contraception [16, 17]. Similarly, a Brazilian study found that while women with SLE were relatively high users of hormonal contraception prior to their diagnosis, more than half were non-users following their diagnosis, and for those still using contraception, it was most likely condoms [9]. This is despite almost half of the women being on teratogenic medications including methotrexate. Low use of high efficacy contraception among women with AICs using fetotoxic medications has been found by others [29, 30]. Although condoms protect against STIs and are effective at preventing pregnancy when used consistently and correctly, given that this method requires user action with every episode of intercourse, typical contraceptive failure rates for condoms have been estimated to be around 20%. The relatively low efficacy of condoms when used as a sole

method of contraception limits their suitability for women with chronic disease, but when used together with a highly effective method such as a LARC or a contraceptive pill they provide protection against STIs and can increase contraceptive protection [31]. However, around half of the women in our study were also predicted to combine their condom use with other low efficacy methods such as withdrawal. The layering of low efficacy methods has been demonstrated among young women, including those with AICs [18, 26]. This is particularly problematic as it has been found that 61% of women with SLE reported using these low efficacy methods and more than half reported having had an unintended pregnancy [32].

Our findings therefore point to a lack of evidence-based advice and support from GPs and specialists. This is particularly important as our recent research has demonstrated that the use of low efficacy contraception has also been found in younger women with AICs [26]. It is essential that individualised contraceptive counselling is included for women of reproductive age from the time of diagnosis and as part of their ongoing care. Switching to low efficacy methods or no contraception after an autoinflammatory diagnosis may be attributed to concerns from health professionals in relation to medical eligibility of combined oral contraceptives and certain AICs, concerns by women themselves, or both [33]. Caution is warranted when prescribing estrogen-containing contraceptives to women with AICs such as RA and SLE due to the elevated risk of venous thromboembolism in those with antiphospholipid syndrome, and in those undergoing IBD-related surgery, while the effectiveness of oral methods will be reduced by malabsorption [34, 35]. LARC are ideal methods for women with AICs wishing to avoid pregnancy as they are highly effective, are not associated with an increased venous thromboembolism risk and are not impacted by malabsorption. However, misperceptions about IUDs persist, particularly regarding their suitability for young and nulliparous women and the risk of pelvic infections [36, 37]. The copper IUD is appropriate for women with AICs wishing to avoid hormonal methods, although its use in Australia is not currently subsidised by the

federal government, unlike progestogen-containing IUDs and implant. Given copper IUDs are suitable for women of all reproductive ages including those in their forties and early fifties as well as for most women with chronic disease, subsidising the copper IUD under the PBS in Australia could facilitate uptake among women with chronic disease.

Despite increasing LARC use being a core outcome of the current Women's Health Strategy currently no formal national guidelines regarding the provision of contraception for women with chronic disease across the reproductive lifecourse exists in Australia [38]. Increased access to, and awareness of current therapeutic guidelines by peak medical associations and key bodies (e.g., eTherapeutic Guidelines) as well as development of referral pathways are required alongside increasing medical education to address the demonstrated lack of expertise and confidence regarding the provision of family planning among GPs and specialists in Australia and other countries [39-41]. Given the increasing prevalence of chronic disease among women of reproductive age, an embedded contraceptive strategy as part of chronic disease management could increase women's agency around contraceptive decision-making. Importantly, although women with diabetes and cardiac disease were found to be using effective contraception at rates similar to the general population, they still require regular review around the suitability of estrogen-containing contraception. The needs of women with cardiac disease are especially difficult to navigate due to variability in potential risks associated with both contraception type and the cardiac disease type and severity and as such a review of reproductive life plans should be part of best practice management for all women with chronic disease.

Conclusion

This study demonstrated that women with chronic disease take up contraception at similar rates to their same aged peers in the community, however women diagnosed with AICs were more likely to engage in low efficacy methods or no contraception. Our study highlights the potential

gaps in the provision of appropriate contraceptive access and care for women with chronic disease, particularly those diagnosed with AICs. This indicates the need for the development of national guidelines as well as a clear coordinated contraceptive strategy from adolescence through to the mid reproductive years and perimenopause encouraging regular contraceptive review during care management as well as training and education for medical professionals to increase support for, and agency among, women with chronic disease. This will not only reduce the occurrence of high-risk unintended pregnancy but facilitate optimal outcomes for planned pregnancies.

ACKNOWLEDGEMENTS

The research on which this paper is based was conducted as part of the Australian Longitudinal Study on Women's Health by the University of Newcastle and the University of Queensland. We are grateful to the Australian Government Department of Health for funding and to the women who provided the survey data. The authors acknowledge the Department of Health and Medicare Australia for providing MBS and PBS data, and the Australian Institute of Health and Welfare (AIHW) as the integrating authority and undertaking the data linkage to the National Death Index (NDI). The authors also acknowledge the following 1) Centre for Health Record Linkage (CHeReL), NSW Ministry of Health and ACT Health for the NSW Admitted Patients and ACT Admitted Patient Care Data Collections; 2) Queensland Health, including the Statistical Services Branch, for the QLD Hospital Admitted Patient Data Collection; 3) Department of Health Western Australia, including the Data Linkage Branch, and the WA Hospital Morbidity Data Collection; 4) SA NT Datalink, SA Health and the Northern Territory Department of Health, for the SA Public Hospital Separations and NT Public Hospital Inpatient Activity Data Collections; 5) The Department of Health Tasmania, and the Tasmanian Data Linkage Unit, for the Public Hospital Admitted Patient Episodes Data Collection; and 6) The

Department of Health and Human Services Victoria, Centre for Victorian Data Linkage, for the Victorian Admitted Episodes Dataset.

SUPPORTING INFORMATION CAPTIONS

Table S1. Comparison of analysed sample to entire cohort at baseline survey (1996).

Table S2. Latent status transition probabilities (tau estimates) from Time 1 (2006) to Time 2 (2012), and from Time 2 (2012) to Time 3 (2018).

Table S3. Summary of LTA model diagnostics for the 1973-78 ALSWH cohort.

Table S4. Latent status membership probabilities (delta estimates) for the five-status model.

Table S5. Full multinomial mixed-effect models for factors associated with contraceptive use among Australian women (2006-2018), examining the impact of any physical chronic disease.

Table S6. Full multinomial mixed-effect models for factors associated with contraceptive use among Australian women (2006-2018), examining the impact of chronic cardiac disease.

Table S7. Full multinomial mixed-effect models for factors associated with contraceptive use among Australian women (2006-2018), examining the impact of diabetes.

Table S8. Full multinomial mixed-effect models for factors associated with contraceptive use among Australian women (2006-2018), examining the impact of asthma.

Table S9. Full multinomial mixed-effect models for factors associated with contraceptive use among Australian women (2006-2018), examining the impact of autoinflammatory disease.

REFERENCES

1. Taft AJ, Shankar M, Black KI, Mazza D, Hussainy S, Lucke JC: Unintended and unwanted pregnancy in Australia: a cross-sectional, national random telephone survey of prevalence and outcomes. *Med J Aust* 2018, 209(9):407-408.
2. Finer LB, Zolna MR: Shifts in intended and unintended pregnancies in the United States, 2001-2008. *Am J Public Health* 2014, 104 (Suppl 1):S43-48.

3. Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M: Pregnancy, sex and hormonal factors in multiple sclerosis. *Mult Scler* 2014, 20(5):527-536.
4. Bundhun PK, Soogund MZ, Huang F: Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016. *J Autoimmun* 2017, 79:17-27.
5. Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP: A meta-analysis on the influence of inflammatory bowel disease on pregnancy. *Gut* 2007, 56(6):830-837.
6. Macintosh MC, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D, Golightly S, Miller A: Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. *BMJ* 2006, 333(7560):177.
7. Khairy P, Ouyang DW, Fernandes SM, Lee-Parritz A, Economy KE, Landzberg MJ: Pregnancy outcomes in women with congenital heart disease. *Circulation* 2006, 113(4):517-524.
8. Holton S, Thananjeyan A, Rowe H, Kirkman M, Jordan L, McNamee K, Bayly C, McBain J, Sinnott V, Fisher J: The fertility management experiences of Australian women with a non-communicable chronic disease: findings from the Understanding Fertility Management in Contemporary Australia Survey. *Matern Child Health J* 2018, 22(6):830-840.
9. Brito MB, Casqueiro JS, Alves FSS, Lopes JB, Alves R, Santiago M: Low prevalence of contraceptive use among Brazilian women of reproductive age with systemic lupus erythematosus. *J Obstet Gynaecol* 2018, 38(7):975-978.
10. Perritt JB, Burke A, Jamshidli R, Wang J, Fox M: Contraception counseling, pregnancy intention and contraception use in women with medical problems: an

- analysis of data from the Maryland Pregnancy Risk Assessment Monitoring System (PRAMS). *Contraception* 2013, 88(2):263-268.
11. Hohmann-Marriott BE: Unplanned pregnancies of women with chronic health conditions in New Zealand. *New Zealand Medical Journal* 2019, 132(1499):11-17.
 12. Chor J, Rankin K, Harwood B, Handler A: Unintended pregnancy and postpartum contraceptive use in women with and without chronic medical disease who experienced a live birth. *Contraception* 2011, 84(1):57-63.
 13. Chuang CH, Chase GA, Bensyl DM, Weisman CS: Contraceptive use by diabetic and obese women. *Womens Health Issues* 2005, 15(4):167-173.
 14. Gawron LM, Gawron AJ, Kasper A, Hammond C, Keefer L: Contraceptive method selection by women with inflammatory bowel diseases: a cross-sectional survey. *Contraception* 2014, 89(5):419-425.
 15. Leverenz DL, Eudy AM, Jayasundara M, Haroun T, McDaniel G, Benjamin Nowell W, Curtis JR, Crow-Hercher R, White W, Ginsberg S *et al*: Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis. *Clin Rheumatol* 2019, 38(4):1207-1212.
 16. Birru Talabi M, Clowse MEB, Blalock SJ, Moreland L, Siripong N, Borrero S: Contraception use among reproductive-age Women with rheumatic diseases. *Arthritis Care Res (Hoboken)* 2018.
 17. DeNoble AE, Hall KS, Xu X, Zochowski MK, Piehl K, Dalton VK: Receipt of prescription contraception by commercially insured women with chronic medical conditions. *Obstet Gynecol* 2014, 123(6):1213-1220.
 18. Harris ML, Coombe J, Forder PM, Lucke JC, Bateson D, Loxton D: Young women's complex patterns of contraceptive use: findings from an Australian cohort study. *Perspect Sex Reprod Health* 2020, 52(3):181-190.

19. Harris ML, Egan N, Forder PM, Coombe J, Loxton D: Contraceptive use among women through their later reproductive years: findings from an Australian prospective cohort study. *PLoS One* 2021, 16(8):e0255913.
20. Dobson AJ, Hockey R, Brown WJ, Byles JE, Loxton DJ, McLaughlin D, Tooth LR, Mishra GD: Cohort Profile Update: Australian Longitudinal Study on Women's Health. *Int J Epidemiol* 2015, 44(5):1547,1547a-1547f.
21. Harris ML, Egan N, Forder PM, Loxton D: Increased chronic disease prevalence among the younger generation: findings from a population-based data linkage study to inform chronic disease ascertainment among reproductive-aged Australian women. *PLoS One* 2021, 16(8):e0254668.
22. World Health Organization: **Obesity: preventing and managing the global epidemic: a report of a WHO consultation.** In: *WHO technical report series*. Geneva, Switzerland: WHO; 2000.
23. Jones RK, Tapales A, Lindberg LD, Frost J: Using longitudinal data to understand changes in consistent contraceptive use. *Perspectives on Sexual and Reproductive Health* 2015, 47(3):131-139.
24. Phillips-Bell GS, Sappenfield W, Robbins CL, Hernandez L: Chronic diseases and use of contraception among women at risk of unintended pregnancy. *J Womens Health (Larchmt)* 2016, 25(12):1262-1269.
25. Bateson D, McNamee K: Perimenopausal contraception: a practice-based approach. *Aust Fam Physician* 2017, 46(6):372-377.
26. Harris ML, Egan N, Forder PM, Bateson D, Loxton D: Patterns of contraceptive use among young Australian women with chronic disease: findings from a prospective cohort study [preprint]. *Research Square* 2021.

27. Lincoln E, McKay R, Schunmann C: Male and female sterilisation. *Obstet Gynaecol Reprod Med* 2020, 30(7):219-224.
28. Richters J, Fitzadam S, Yeung A, Caruana T, Rissel C, Simpson JM, de Visser RO: Contraceptive practices among women: the second Australian study of health and relationships. *Contraception* 2016, 94(5):548-555.
29. Birru Talabi M, Clowse MEB, Schwarz EB, Callegari LS, Moreland L, Borrero S: Family Planning Counseling for Women With Rheumatic Diseases. *Arthritis Care Res (Hoboken)* 2018, 70(2):169-174.
30. Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty E, Schwarz EB: Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality? *Arthritis Care Res (Hoboken)* 2011, 63(3):358-365.
31. Trussell J: Understanding contraceptive failure. *Best Pract Res Clin Obstet Gynaecol* 2009, 23(2):199-209.
32. Dalkilic E, Tufan AN, Oksuz MF, Sahbazlar M, Coskun BN, Seniz N, Pehlivan Y, Inanc M: Comparing female-based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population. *Int J Rheum Dis* 2014, 17(6):653-657.
33. Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit: **Faculty of Sexual and Reproductive Healthcare Clinical Guidance Report**. In: *Contraceptive choices for women with cardiac disease* UK: FSRH; 2014.
34. Zapata LB, Paulen ME, Cansino C, Marchbanks PA, Curtis KM: Contraceptive use among women with inflammatory bowel disease: a systematic review. *Contraception* 2010, 82(1):72-85.
35. Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF: Thromboembolic events and cardiovascular mortality in inflammatory bowel

- diseases: a meta-analysis of observational studies. *J Crohns Colitis* 2014, 8(6):469-479.
36. Tepper NK, Curtis KM, Nanda K, Jamieson DJ: Safety of intrauterine devices among women with HIV: a systematic review. *Contraception* 2016, 94(6):713-724.
37. Farr SL, Folger SG, Paulen ME, Curtis KM: Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review. *Contraception* 2010, 82(1):64-71.
38. Australian Government Department of Health: **National women's health strategy: 2020-2030**. In. Canberra: Commonwealth of Australia; 2020.
39. Toomey D, Waldron B: Family planning and inflammatory bowel disease: the patient and the practitioner. *Fam Pract* 2013, 30(1):64-68.
40. Mazza D, Chapman A, Michie S: Barriers to the implementation of preconception care guidelines as perceived by general practitioners: a qualitative study. *BMC Health Serv Res* 2013, 13:36.
41. **eTG complete [digital]**. In. Melbourne: Therapeutic Guidelines Limited; 2020 Dec.